Scancell Holdings (FRA:SCP) Change In Receivables : €5.84 Mil (TTM As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Change In Receivables?

Scancell Holdings's change in receivables for the quarter that ended in Oct. 2023 was €0.07 Mil. It means Scancell Holdings's Accounts Receivable declined by €0.07 Mil from Apr. 2023 to Oct. 2023 .

Scancell Holdings's change in receivables for the fiscal year that ended in Apr. 2023 was €0.13 Mil. It means Scancell Holdings's Accounts Receivable declined by €0.13 Mil from Apr. 2022 to Apr. 2023 .

Scancell Holdings's Accounts Receivable for the quarter that ended in Oct. 2023 was €0.55 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Scancell Holdings's liquidation value for the six months ended in Oct. 2023 was €-19.82 Mil.

Scancell Holdings Change In Receivables Historical Data

The historical data trend for Scancell Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Change In Receivables Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Change In Receivables

Get a 7-Day Free Trial

-0.67

0.35

-0.69

0.39

0.13

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Change In Receivables	Get a 7-Day Free Trial															0.14	0.25	-5.71	5.77	0.07

Scancell Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €5.84 Mil.

Scancell Holdings (FRA:SCP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Scancell Holdings's Days Sales Outstanding for the quarter that ended in Oct. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.549	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Scancell Holdings's accounts receivable are only considered to be worth 75% of book value:

Scancell Holdings's liquidation value for the quarter that ended in Oct. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.086	-	35.314	+	0.75 * 0.549	+	0.5 * 0
=	-19.82

Scancell Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines